Cargando…

Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Eli Lilly) of abemaciclib (Verzenios) to submit evidence for the clinical and cost effectiveness of this drug in combination with endocrine therapy (ET) for the treatment of adult patients with hormone receptor (H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orozco Leal, Giovany, Armstrong, Nigel, Kernohan, Ashleigh, Ahmadu, Charlotte, Coughlan, Diarmuid, McDermott, Kevin, Duffy, Steven, O’Meara, Susan, Robinson, Tomos, Vale, Luke, Kleijnen, Jos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034868/ https://www.ncbi.nlm.nih.gov/pubmed/36952138 http://dx.doi.org/10.1007/s40273-023-01259-6

Ejemplares similares

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2023)

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2022)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Incorporating economic methods into Cochrane systematic reviews: case studies in brain tumour research
por: Kernohan, Ashleigh, et al.
Publicado: (2023)

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem, et al.
Publicado: (2023)

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: van Asselt, Antoinette D. I., et al.
Publicado: (2023)

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2022)

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2018)

Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2023)

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2017)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2018)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
por: Cejuela, Mónica, et al.
Publicado: (2023)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
por: Tolaney, Sara M., et al.
Publicado: (2022)

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2020)

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
por: Toi, Masakazu, et al.
Publicado: (2022)

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
por: Di Leo, Angelo, et al.
Publicado: (2018)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2019)

Abemaciclib for breast cancer
Publicado: (2020)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
por: Davie, Alison, et al.
Publicado: (2023)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal
por: Thielen, Frederick W., et al.
Publicado: (2018)

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2019)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
por: Sledge, George W., et al.
Publicado: (2019)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dpa3khvi3s7uvg793qgebhask2